Trial reportCancer discovery2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 235 citations in OpenAlex.
- A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.Investigational new drugs · 2025Trial
- Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Trial
- Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial.BMC cancer · 2024Trial
- Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC.Signal transduction and targeted therapy · 2022Trial
- Application and mechanistic research of novel therapeutic strategies in cisplatin-resistant small cell lung cancer.Annals of medicine · 2026Review
- Structural basis of PARP2 recognition of nucleosomal DNA breaks and inhibitor trapping.Nucleic acids research · 2026Article
- Article
- Integrating molecular subtypes, genomics and functional dependencies to identify context-specific therapeutic vulnerabilities in small cell lung cancer.Biomarker research · 2026Review
- SLFN11 enhances cisplatin sensitivity in pediatric cancer via activation of stress-response and suppression of survival pathways.British journal of cancer · 2026Article
- Review
- Traditional Chinese medicine monotherapy in extensive-stage small cell lung cancer: A Case Report.Medicine · 2026Article
- [Expert Consensus on Immunotherapy for Extensive-stage Small Cell Lung Cancer Based on Molecular Subtyping].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Mechanisms of resistance in small cell lung cancer.Chinese medical journal · 2026Review
- Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab.Cancer discovery · 2026Article
- Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer.Science advances · 2026Review
- MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling.Current issues in molecular biology · 2026Article
- SeSA-HCPT: A dual-targeting agent that induces DNA damage and inhibits repair for castration-resistant prostate cancer therapy.iScience · 2026Article
- Denosumab Regulates Titanium Particles-Induced Macrophages Inflammation and Osteolysis by Targeting the ST18/PARP1 Interaction.Orthopaedic surgery · 2026Article
- KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage.bioRxiv : the preprint server for biology · 2026Article
- Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies.Frontiers in oncology · 2026Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 4 institutions in 1 country.
Anna F FaragoMassachusetts General Hospital Cancer Center, Boston, Massachusetts. afarago@mgh.harvard.edu bjdrapkin@partners.org.
Beow Y YeapMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Marcello StanzioneMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Yin P HungMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0002-8568-1591
Rebecca S HeistMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
J Paul MarcouxDana-Farber Cancer Center, Boston, Massachusetts.
Jun ZhongMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Deepa RangachariDana-Farber Cancer Center, Boston, Massachusetts.
David A BarbieDana-Farber Cancer Center, Boston, Massachusetts.
Sarah PhatMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
David T MyersMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Robert MorrisMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Marina KemMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Taronish D DubashMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Elizabeth A KennedyMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Subba R DigumarthyDana-Farber Cancer Center, Boston, Massachusetts.ORCID 0000-0003-4041-6716
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0002-8965-6991
Aaron N HataMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Daniel A HaberMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Michael S LawrenceMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Alice T ShawMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Mari Mino-KenudsonMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0002-9092-2265
Nicholas J DysonMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Benjamin J DrapkinMassachusetts General Hospital Cancer Center, Boston, Massachusetts. afarago@mgh.harvard.edu bjdrapkin@partners.org.
Massachusetts General Hospital · USBeth Israel Deaconess Medical Center · USHarvard University · USHoward Hughes Medical Institute · US
Funding
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MUsing patient-derived models to understand drug responses in SCLCU01CA220323 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DYSON, NICHOLAS J · 2018 to 2022
$3.1MHoward Hughes Medical InstituteNCI NIH HHS K12 CA087723NCI NIH HHS U01 CA220323NCI NIH HHS U24 CA213274
Abstract
Small-cell lung cancer (SCLC) is an aggressive malignancy in which inhibitors of PARP have modest single-agent activity. We performed a phase I/II trial of combination olaparib tablets and temozolomide (OT) in patients with previously treated SCLC. We established a recommended phase II dose of olaparib 200 mg orally twice daily with temozolomide 75 mg/m
Indexed as
AdultAgedAged, 80 and overAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorComputational BiologyDrug Resistance, NeoplasmFemaleHumansLung NeoplasmsMaleMiceMiddle AgedNeoplasm Recurrence, LocalPhthalazinesBiomarkers, TumorolaparibPhthalazinesPiperazinesTemozolomide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.